DDInter608 DDInter1376
Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Duloxetine {u} (Compound) resembles {v} (Compound) Atomoxetine
Duloxetine {u} (Compound) binds {v} (Gene) CYP1A2
Duloxetine {u} (Compound) upregulates {v} (Gene) HMOX1
Duloxetine {u} (Compound) palliates {v} (Disease) bipolar disorder
Duloxetine {u} (Compound) is included by {v} (Pharmacologic Class) Norepinephrine Uptake Inhibitors
Duloxetine {u} (Compound) downregulates {v} (Gene) CDCA4
Duloxetine {u} (Compound) causes {v} (Side Effect) Acute liver injury
Duloxetine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Esomeprazole
Duloxetine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pantoprazole
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ioflupane I-123
Duloxetine (Compound) resembles Atomoxetine (Compound)
Duloxetine (Compound) binds CYP1A2 (Gene)
Duloxetine (Compound) upregulates HMOX1 (Gene)
Duloxetine (Compound) palliates bipolar disorder (Disease)
Duloxetine (Compound) is included by Norepinephrine Uptake Inhibitors (Pharmacologic Class)
Duloxetine (Compound) downregulates CDCA4 (Gene)
Duloxetine (Compound) causes Acute liver injury (Side Effect)
Duloxetine may cause a minor interaction that can limit clinical effects when taken with Esomeprazole
Duloxetine may cause a minor interaction that can limit clinical effects when taken with Pantoprazole
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123